Asana BioSciences Relocates Operations To Lawrenceville, New Jersey
08/24/2016
“This move was necessary to further our vision of building an oncology-focused biopharmaceutical company,” said Sandeep Gupta, Ph.D., president and chief executive officer of Asana BioSciences. “As we continue to expand and grow, our new Princeton area location makes it ideal for us to attract key scientific and medical talent within the Central New Jersey and Philadelphia life sciences corridor.”
According to company officials, Asana continues to advance its portfolio of differentiated targeted therapies to help address major unmet medical needs, including a novel CYP17 inhibitor for prostate cancer and a dual Syk/JAK inhibitor for non-Hodgkin’s lymphoma that are in phase I/II clinical trials.
Asana BioSciences, an independent member of The Amneal Alliance of companies, is a research and development company, specializing in the discovery and development of novel drug candidates, including an antibody-drug conjugate. Asana’s portfolio consists of multiple early-stage development candidates in a variety of therapeutic areas, including oncology, pain and inflammation, among others. Over the past year, it has been adding key talent to its team, including the appointment of a chief medical officer and expansion of its scientific advisory board.
Project Announcements
Lumber Liquidators Plans Lawrenceburg, Tennessee, Headquarters Operations
04/16/2026
Canada-Based Bioriginal Food & Science Plans Grand Junction, Colorado, Operations
04/15/2026
Sesajal Plans Temple, Texas, Warehousing-Production Operations
04/15/2026
Hitachi Energy Plans Cary, North Carolina, Operations
04/15/2026
Mercedes-Benz Expands Tuscaloosa County, Alabama, Production Operations
04/14/2026
Qblox Plans Canton, Massachusetts, Operations
04/14/2026
Most Read
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Last Word: Don’t Lose by Winning
Q1 2026
-
Advanced Manufacturing Isn’t a Buzzword—It’s a Different Location Strategy
Q1 2026
-
40th Annual Corporate and 22nd Annual Consultant Site Selection Survey Results
Q1 2026